Affimed NV (AFMD)
5.62
-0.10
(-1.75%)
USD |
NASDAQ |
Jun 26, 11:10
Affimed SG&A Expense (Quarterly): 4.862M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 4.862M |
December 31, 2023 | 6.642M |
September 30, 2023 | 5.859M |
June 30, 2023 | 6.844M |
March 31, 2023 | 7.357M |
December 31, 2022 | 8.759M |
September 30, 2022 | 8.149M |
June 30, 2022 | 8.920M |
March 31, 2022 | 7.905M |
December 31, 2021 | 8.523M |
September 30, 2021 | 8.066M |
June 30, 2021 | 6.555M |
March 31, 2021 | 5.406M |
December 31, 2020 | 4.923M |
September 30, 2020 | 4.040M |
June 30, 2020 | 2.87M |
March 31, 2020 | 3.89M |
December 31, 2019 | 2.990M |
September 30, 2019 | 3.102M |
June 30, 2019 | 2.631M |
March 31, 2019 | 2.765M |
December 31, 2018 | 3.476M |
September 30, 2018 | 2.778M |
Date | Value |
---|---|
June 30, 2018 | 2.584M |
March 31, 2018 | 2.504M |
December 31, 2017 | 2.232M |
September 30, 2017 | 2.206M |
June 30, 2017 | 2.166M |
March 31, 2017 | 2.393M |
December 31, 2016 | 2.248M |
September 30, 2016 | 2.434M |
June 30, 2016 | 2.22M |
March 31, 2016 | 2.309M |
December 31, 2015 | 2.140M |
September 30, 2015 | 2.298M |
June 30, 2015 | 1.852M |
March 31, 2015 | 2.085M |
December 31, 2014 | 2.181M |
September 30, 2014 | 0.33M |
June 30, 2014 | -6.013M |
March 31, 2014 | 6.487M |
December 31, 2013 | 0.9284M |
September 30, 2013 | 5.221M |
June 30, 2013 | 1.962M |
March 31, 2013 | 1.218M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.631M
Minimum
Jun 2019
8.920M
Maximum
Jun 2022
5.915M
Average
6.207M
Median
SG&A Expense (Quarterly) Benchmarks
CureVac NV | 18.25M |
InflaRx NV | 5.473M |
MorphoSys AG | -9.867M |
BioNTech SE | 144.03M |
Immatics NV | 12.65M |